About Hypha Discovery
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development. Hypha is an expert in the scalable synthesis and purification of drug metabolites and oxidised derivatives of lead compounds, and possesses a wealth of experience in the production, purification and structure elucidation of natural products.
Follow us on LinkedIn.One-Stop Metabolite Shop
Hypha recently launched the “One Stop Metabolite Shop” which offers clients the opportunity to access phase I and phase II metabolites, from microgram scale for MetID through to multi mg / gram scale for further evaluation and provision of bioanalytical standards.
We offer a comprehensive suite of techniques for provision of even the most difficult-to-synthesise metabolite, comprising chemical synthesis, recombinant enzymes such as PolyCYPs, microbial biotransformation, mammalian liver fractions as well as the purification of metabolites from biological matrices. Hypha scientists are also experts in structural elucidation via NMR spectroscopy.
NEW PolyCYPs®+ biocatalysis kits
PolyCYPs®+ is a new product comprising 18 PolyCYP isoforms and broadened by the addition of other phase I enzymes. Human aldehyde oxidase (AOX1) and the main human hepatic flavin-containing monooxygenase (FMO3) are now included in the kit, with other human FMO isoforms available soon. Inclusion of new PolyCYPs isoforms broadens coverage of reactions, and have been proven to metabolise some low turnover drugs and produce multi-step oxidised metabolites.
Download an info sheet on PolyCYPs+
Click here to find out more about PolyCYPs+ kits
NEWS & EVENTS
WEBINARS – If you missed the recent webinars on Hypha’s new “One-stop metabolite shop” featuring our enhanced PolyCYPs+ kit and a newly developed late-stage chemical glucuronidation screen, contact us for a link to a recording.
18th – 19th February 2020, Manchester, UK Dr Julia Shanu-Wilson will be giving a talk on “Integration of biocatalysis into medicinal chemistry programs for late-stage oxidation using PolyCYPs enzymes” 17th April 2020, San Diego, US Hypha’s CEO Liam Evans will be attending this meeting which focuses on tools and strategies for predicting, optimizing, and Improving PKPD and safety 30th April 2020, Hatfield, UK. Frank Scheffler our Head of Business Development will be attending this great one day meeting in Hatfield catching up on all the recent progress in pharma medchem. 5th-6th May 2020, Liverpool, UK. Julia and Frank will be exhibiting at this meeting and giving a talk entitled “One-Stop Metabolite Shop; Employing Multiple Tools for Accessing Drug Metabolites.” 28th June – 1st July 2020, New York City, USA Julia and Liam are looking forward to attending this meeting in NYC. August 16 – 20 2020, San Francisco, USA Liam will be attending this meeting and giving a talk in the session on “Technologies and Predictive Tools for Metabolite Generation, Identification and Assessment.”Come and meet us at the following events
SCI/RSC Applied Late-stage Functionalisation: Where Chemistry meets Biology
Drug Discovery Chemistry: Lead Optimization for Drug Metabolism & Safety
31st Symposium on Medicinal Chemistry in Eastern England
5th RSC / DMDG / DMG
New Perspectives in DMPK
ACS Medi 37th National Medicinal Chemistry Symposium
260th ACS National Meeting & Exposition
Our brochure on drug metabolites and C-H activated derivatives features interesting case studies and client projects completed using microbial biotransformation. Topics include: Let us know if you would like a copy of a paper published last year in Xenobiotica entitled Microbial Biotransformation – An Important Tool for the Study of Drug Metabolism, which describes some interesting projects Hypha have undertaken for Merck and Janssen with several difficult-to-synthesise hydroxylated and glucuronidated metabolites. Read the abstract at http://bit.ly/2xb6H9d In a recent newsletter we described a case study illustrating the use of microbial biotransformation to produce scalable quantities of glucuronides, focusing on the synthesis of acyl glucuronides of carboxylic acid-containing drugs. Access a pdf of the newsletter on glucuronides of carboxylic acid-containing drugs Hypha’s PolyCYPs enzymes have been routinely used by pharma and agchem companies for producing metabolites. One application involves direct comparison of radiometric profiles of PolyCYPs and regulatory study samples. In this study by Charles River, a radiolabelled agrochemical compound was incubated with PolyCYPs and the metabolites matched with those detected in goat faeces, as part of an mass balance and disposition study, thereby providing an immediate route to access and scale-up metabolites. Click here for a link to an illustration of the results of this study.Download a copy of our brochure on drug metabolites and C-H activated derivatives
Hypha’s latest metabolite project update
